Your browser doesn't support javascript.
loading
The Merit of Tyrosine Kinase inhibitors in the adjuvant setting of high-risk renal cell carcinoma Ameta-Analysis
LMJ-Lebanese Medical Journal. 2019; 67 (suppl.): 39-42
in English, French | IMEMR | ID: emr-206753
ABSTRACT

Background:

Loco-regional renal cell carcinoma [RCC] accounts for 15 to 20 percent of patients with RCC, with a risk of post-surgical relapse of 40 percent [1,2]. Following the adoption of tyrosine kinase inhibitors [TKIs] as the first-line treatment of metastatic RCC, multiple studies evaluated Sunitinib [3,4] and Pazopanib [5] in the adjuvant setting of high-risk resected RCC. However, these studies have yielded inconclusive results, and there are currently no meta-analyses combining the results of all trials evaluating TKIs in the adjuvant setting of high-risk RCC. The aim was to perform a meta-analysis to evaluate and compare the possible benefit of Sunitinib and Pazopanib on diseasefree survival [DFS] in the adjuvant setting of high-risk RCC
Search on Google
Index: IMEMR (Eastern Mediterranean) Type of study: Controlled clinical trial Language: English / French Journal: Lebanese Med. J. Year: 2019

Similar

MEDLINE

...
LILACS

LIS

Search on Google
Index: IMEMR (Eastern Mediterranean) Type of study: Controlled clinical trial Language: English / French Journal: Lebanese Med. J. Year: 2019